Charles Schwab Investment Management Inc Immuneering Corp Transaction History

Charles Schwab Investment Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$7.21 - $10.68 $39,453 - $58,440	5,472 Added 9.94%	60,512 $464,000
Q2 2023 Aug 09, 2023	BUY	$6.49 - $13.36 $357,209 - $735,334	55,040 New	55,040 $558,000
Q2 2022 Aug 15, 2022	SELL	$3.89 - $7.81 $176,765 - $354,894	-45,441 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $155,564 - $408,507	24,044 Added 112.37%	45,441 $295,000
Q4 2021 Feb 11, 2022	BUY	$16.12 - $31.02 $18,715 - $36,014	1,161 Added 5.74%	21,397 $346,000
Q3 2021 Nov 16, 2021	BUY	$17.0 - $32.84 $344,012 - $664,550	20,236 New	20,236 $538,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $53.8M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.